Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
Portfolio Pulse from Benzinga Newsdesk
Nasdaq has granted BiondVax Pharmaceuticals an extension to regain compliance with listing rules. The company now has until February 2023 to meet the minimum $1.00 bid price requirement.
August 04, 2023 | 10:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BiondVax Pharmaceuticals has been granted an extension by Nasdaq to regain compliance with listing rules. This could potentially stabilize the company's stock price in the short term.
The extension granted by Nasdaq allows BiondVax more time to meet the minimum bid price requirement, which could potentially prevent a delisting. This news could stabilize the company's stock price in the short term as it reduces immediate pressure on the company.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100